Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2451 and GLPG2222 in Healthy Females
NCT02788721Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG2451 in cystic fibrosis (CF) (4 arms), sponsored by Galapagos NV. Primary endpoint: Proportion of subjects with adverse events. Started Apr 2016; status: completed.
02
Drugs
GLPG2451
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02788721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788721.